Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06172478 · ClinicalTrials.gov registry record · Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 2 study of Melanoma and Head and Neck Cancer, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 740
- Enrollment target
- 20
- Study locations
NCT06172478 is a Phase 2 study of Melanoma and Head and Neck Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 740 participants, roughly in line with the 704-participant average among 266 other Melanoma trials with a reported enrollment target. The trial reports 20 study locations across 12 states.
The verdict
NCT06172478, a Phase 2 study of Melanoma and Head and Neck Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 740 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.
Conditions Studied
Interventions
- DRUG HER3-DXd
Study Locations (20)
Other
- Chris O'Brien Lifehouse - Camperdown
- Icon Cancer Centre Chermside - Chermside
- Monash Medical Centre Clayton - Clayton
- Icon Cancer Centre Hobart - Hobart
- Icon Cancer Centre Townsville - Hyde Park
- Cliniques Universitaires Saint-Luc - Brussels
- UZA - Edegem
Minnesota
- Health Partners Frauenshuh Cancer Center - Saint Louis Park
- Health Partners Cancer Center at Regions Hospital - Saint Paul
New York
- Roswell Park Cancer Institute IDS - Buffalo
- Memorial Sloan Kettering Hospital - New York
California
- City of Hope - Duarte
Connecticut
- Yale Cancer Center - New Haven
Florida
- AdventHealth Medical Group Oncology Research at Celebration - Kissimmee
Illinois
- University of Illinois Cancer Center - Chicago
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 740 participants |
| Start Date | 2024-02-26 |
| Est. Completion | 2028-10-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06172478
The ClinicalTrials.gov registry entry for NCT06172478 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 740 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 704-participant average among 266 other Melanoma trials with a reported enrollment target. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which HER3-DXd is the first listed.
NCT06172478 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT06172478 about?
NCT06172478 is a clinical study titled "A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors". This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric ca...
What is the current status of trial NCT06172478?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 740 participants. The study started on 2024-02-26. Estimated completion is 2028-10-10.
What conditions does trial NCT06172478 study?
This clinical trial studies the following conditions: Melanoma, Head and Neck Cancer, Advanced Solid Tumor, Endometrial Cancer, Bladder Cancer.
What interventions are being tested in trial NCT06172478?
The interventions under investigation include: HER3-DXd (DRUG).
Who is sponsoring clinical trial NCT06172478?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06172478 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.